Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Elliot Wilbur has maintained an Outperform rating on ANI Pharmaceuticals and raised the price target from $81 to $83.
September 18, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reaffirmed its Outperform rating for ANI Pharmaceuticals and increased the price target from $81 to $83, indicating a positive outlook.
The increase in price target from $81 to $83 by Raymond James suggests a positive outlook for ANI Pharmaceuticals, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100